周剂量泰索帝联合顺铂治疗77例晚期非小细胞肺癌临床观察  

The clinical study of weekly taxotere conbined with cisplatin in the treatment of advanced Non-small cell lung cancer

作　　者：程颖[1] 柳影[1] 张彩霞[1] 鲍慧铮[1] 马丽霞[1] 

机构地区：[1]吉林省肿瘤医院化疗一科,吉林长春130012

出　　处：《吉林医学》2006年第7期709-710,共2页Jilin Medical Journal

摘　　要：目的：观察周剂量泰索帝联合顺铂方案治疗一线及二线晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法：2000年-2005年收治的77例ⅢB-Ⅳ期NSCLC患者，分为初治组和复治组，初治组36例，复治组41例，泰索帝35mg／m^2静脉点滴1h，第1、8天，DDP40mg静脉点滴，第1-3天，21d为1周期。结果：77例中CR6例，PR19例，NC42例，PD10例。总有效率（RR）为32．5％（25／77）。初治组RR44．4％（16／36），复治组RR24．3％（10／41）。全组中位TTP为4个月（2-12个月），中位生存期13月，1年生存率为65．7％，2年生存率14．7％，主要毒副反应为骨髓抑制；白细胞下降占32．46％（25／77），Ⅲ-Ⅳ度2．59％（2／77）；非血液学毒性轻微。全组无治疗相关性死亡。结论：周剂量泰索帝联合顺铂方案一线及二线治疗晚期非小细胞肺癌均疗效较好，耐受性佳。Objective To observe the efficacy and toxicity of weekly Taxotere combined cisplatin in the treatment of patients with advanced non-small cell lung cancer. Method 77cases with advanced NSCLC were enrolled into the study.Taxotere was administered on days 1,8 at the dose of 35mg/m^3,given by infusion for lh ,and cisplatin at a dose 40mg on days 1-3.The chemotherapy was repeated for 21 days. Results There were 6CR,19PR,42NC and 10 PD ,the overall response rate was 32.5%,with response rate being 44.4%（16/36）in the initial group ,and 24.3%（10/41）in the repeated group.The major toxic reactions in two groups were bone marrow suppression （2.59% in grade Ⅲ-Ⅳ） which is alopecia,which were well tolerated by most of the patients.The none-hematological toxicity was mild. Conclusion The regiment of weekly taxotere plus cisplatin is effective and well-tolerated in the first-line or second-line treatment of advanced NSCLC patients.

关 键 词：泰索帝 顺铂 非小细胞肺癌 周疗法 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]